Evidence map›Paper›PMID 40717199›Full record

Trial reportObesity (Silver Spring, Md.)2025

Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials.

Evgenia Gourgari, Gitanjali Srivastava, Aaron S Kelly, Donna Mojdami, Dachuang Cao, Madhumita A Murphy, Chrisanthi A Karanikas, Clare J Lee

3 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Obesity (Silver Spring, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04184622. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04184622 phase3completed

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Ran2019Enrolled2,539Registered outcomes26Posted comparisons49ConditionsObesity, OverweightArmsPlacebo, Tirzepatide
Open the trial in the graph
NCT04657016 phase3completed

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)

Ran2021Enrolled579Registered outcomes22Posted comparisons22ConditionsObesity, OverweightArmsPlacebo, Tirzepatide
Open the trial in the graph
NCT04660643 phase3completed

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)

Ran2021Enrolled783Registered outcomes26Posted comparisons41ConditionsObesity, OverweightArmsPlacebo, Tirzepatide
Open the trial in the graph
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Evgenia GourgariDivision of Pediatric Endocrinology, Department of Pediatrics, Georgetown University, Washington, DC, USA.ORCID https://orcid.org/0000-0002-5788-7955
Gitanjali SrivastavaDivision of Diabetes, Endocrinology & Metabolism, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0002-8326-3089
Aaron S KellyDepartment of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0001-8530-107X
Donna MojdamiEli Lilly Canada Inc., Toronto, Ontario, Canada.
Dachuang CaoEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0003-2291-9037
Madhumita A MurphyEli Lilly and Company, Indianapolis, Indiana, USA.
Chrisanthi A KaranikasEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0009-0008-0614-8264
Clare J LeeEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0002-0824-0207

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

objectivePeople with early-onset obesity (diagnosed at age < 25 years) may present with more cardiometabolic abnormalities and obesity-related complications. This post hoc analysis assessed baseline characteristics and body weight (BW) changes with tirzepatide in people with early- versus later-onset obesity.

methodsParticipants (N = 3782) from SURMOUNT-1, SURMOUNT-3, and SURMOUNT-4 randomized to tirzepatide or placebo were included. Baseline characteristics and changes in BW and cardiometabolic risk factors at 72/88 weeks were assessed.

resultsIn SURMOUNT-1, participants with early- versus later-onset obesity had longer mean obesity duration (20 ± 12 vs. 11 ± 8 years), higher BMI (40 ± 7 vs. 37 ± 6 kg/m

conclusionsIn this post hoc analysis, participants with early- versus later-onset obesity exhibited a mixed profile of metabolic health at baseline, including a higher degree of central adiposity and lower HbA1c and SBP. Improvements in BW and cardiometabolic markers with tirzepatide were similar between subgroups.

trial registrationClinicalTrials.gov identifiers: NCT04184622, NCT04657016, NCT04660643.

Indexed as

ObesityAdolescentAdultAge of OnsetBlood PressureBody Mass IndexBody WeightCardiometabolic Risk FactorsFemaleGlycated HemoglobinHumansMaleTirzepatideTreatment OutcomeTriglyceridesWaist CircumferenceGlycated HemoglobinTirzepatideTriglyceridesearly‐onsetobesitytirzepatide

Identifiers

PMID40717199
PMCPMC12381612

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.